Satisfaction of young women with Estradiol Valerate/Dienogest in real clinical practice in Russia: results of prospective multicenter observational study Q-SWAN

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective: To evaluate satisfaction in young women (18–35 years old) with a drug containing estradiol valerate/dienogest (E2V/DNG) over a 6-month period in real clinical practice in Russia.

Materials and methods: This was a prospective multicenter study that assessed satisfaction of 504 women (average age is 27.8 years) with the contraceptive containing E2V/DNG. The characteristics of menstrual bleeding, sexual function, and women’s decision to continue using the contraceptive were evaluated in two subgroups: in the presence and absence of abnormal uterine bleeding (AUB). The satisfaction of doctors with this method of contraception was also assessed.

Results: It was found that 98.4% of women and 100% of doctors were “very satisfied” or “satisfied” with this method of contraception, regardless of the presence or absence of AUB. There was a significant decrease in the intensity, duration of menstrual bleeding and pain, and in the frequency of intermenstrual bleeding compared with the baseline indicator. Normalization of the parameters of the FSFI questionnaire was observed in most of the patients (89.7%), although initially these parameters could indicate sexual dysfunction in almost half of the patients (46.0%). The contraceptive E2V/DNG was well tolerated by women, and the overall rate of adverse events was 7.1%. Most women (97.8%) decided to continue taking the medication after completing the study.

Conclusion: The results of the study showed high satisfaction of young Russian women and doctors with the use of E2V/DNG, regardless of the presence or absence of AUB. The medication has a positive effect on the characteristics of bleeding/cycle control and on the quality of sexual function, therefore, the women demonstrated a high adherence to this method of contraception.

Full Text

Restricted Access

About the authors

Vera N. Prilepskaya

Academician V.I. Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Author for correspondence.
Email: vprilepskaya@mail.ru
ORCID iD: 0000-0003-3993-7629

Dr. Med. Sci., Professor, Honored Scientist of the Russian Federation, Head of the Scientific Polyclinic Department

Russian Federation, Moscow

Elena N. Andreeva

National Medical Research Center for Endocrinology, Ministry of Health of Russia; Russian University of Medicine, Ministry of Health of Russia

Email: gynec@endocrincentr.ru

Dr. Med. Sci., Professor, Deputy Director – Director of the Institute of Reproductive Medicine, Professor at the Department of Obstetrics, Gynecology and Reproductive Medicine

Russian Federation, Moscow; Moscow

References

  1. Дикке Г.Б. Потребности, ожидания и сомнения у пользователей гормональными контрацептивами. Гинекология. 2020; 22(1): 33-7. [Dikke G.B. Needs, expectations and doubt users of hormonal contraceptives. Gynecology. 2020; 22(1): 33-7. (in Russian)]. https://dx.doi.org/10.26442/ 20795696.2020.1.200044.
  2. Шереметьева Е.В., Андреева Е.Н. Индивидуальное консультирование молодых женщин по вопросам контрацепции в реальной клинической практике. Проблемы репродукции. 2022; 28(4): 89-96. [Sheremetyeva E.V., Andreeva E.N. Individualized contraceptive counseling for young women in clinical practice. Russian Journal of Human Reproduction. 2022; 28(4): 89-96. (in Russian)]. https://dx.doi.org/10.17116/repro20222804189.
  3. Nappi R.E., Vermuyten N., Bannemerschult R. Missed opportunities in contraceptive counselling: findings from a European survey-based study with simulated patient consultation. Eur. J. Contracept. Reprod. Health Care. 2022; 27(2): 85-94. https://dx.doi.org/10.1080/13625187.2021.2010040.
  4. Bitzer J., Marin V., Lira J. Contraceptive counselling and care: a personalized interactive approach. Eur. J. Contracept. Reprod. Health Care. 2017; 22(6): 418-23. https;//dx.doi.org/10.1080/13625187.2017.1414793.
  5. Cavallaro F.L., Benova L., Owolabi O.O., Ali M. A systematic review of the effectiveness of counselling strategies for modern contraceptive methods: what works and what doesn't? BMJ Sex. Reprod. Health. 2020; 46(4): 254-69. https://dx.doi.org/10.1136/bmjsrh-2019-200377.
  6. FSRH Clinical Effectiveness Unit. FSRH clinical guideline: combined hormonal contraception (January 2019, Amended October 2023). https://dx.doi.org/10.1136/bmjsrh-2018-CHC.
  7. Прилепская В.Н., Абакарова П.Р., Яроцкая Е.Л. Современная контрацепция и качество жизни женщины. Доктор Ру. 2017; 3: 37-42. [Prilepskaya V.N., Abakarova P.R., Yarotskaya Ye.L. Modern Contraception and Women’s Quality of Life. Doctor.Ru. 2017; (3): 37-42. (in Russian)].
  8. Дикке Г.Б. Отказ от ранее выбранного метода контрацепции и стратегии повышения приверженности. Проблемы репродукции. 2017; 23(5): 54-60. [Dikke G.B. Failure from the previously selected method of contraception and strategy for improving commitment. Russian Journal of Human Reproduction. 2017; 23(5): 54-60. (in Russian)]. https://dx.doi.org/10.17116/ repro201723554-60.
  9. Le Guen M., Schantz C., Règnier-Loilier A., de La Rochebrochard E. Reasons for rejecting hormonal contraception in Western countries: A systematic review. Soc. Sci. Med. 2021; 284: 114247. https://dx.doi.org/ 10.1016/j.socscimed.2021.114247.
  10. Graziottin A. The shorter, the better: a review of the evidence for a shorter contraceptive hormone-free interval. Eur. J. Contracept. Reprod. Health Care. 2016; 21(2): 93-105. https://dx.doi.org/10.3109/13625187.2015.1077380.
  11. Андреева Е.Н., Шереметьева Е.В. Режимы контрацепции: повышение приверженности женщин современным комбинированным оральным контрацептивам с максимально коротким безгормональным интервалом. Гинекология. 2020; 22(2): 46-50. [Andreeva E.N., Sheremetyeva E.V. Contraception modes: increasing women’s commitment to modern combined oral contraceptives with the shortest possible hormone-free interval. Gynecology. 2020; 22(2): 46-50. (in Russian)]. https://dx.doi.org/10.26442/ 20795696.2020.2.200128.
  12. Актуальная версия инструкции препарата «Клайра» от 31.05.2023. Номер РУ: ЛП-№ (002448)-(РГ-RU). [The current version of the instructions of the drug Qlaira dated 05/31/2023. RU number: LP-No. (002448)-(RG-RU). (in Russian)].
  13. Nelson A., Parke S., Mellinger U., Zampaglione E., Schmidt A. Efficacy and safety of a combined oral contraceptive containing estradiol valerate/dienogest: results from a clinical study conducted in North America. J. Womens Health (Larchmt). 2014; 23(3): 204-10. https://dx.doi.org/10.1089/ jwh.2013.4320.
  14. Yu Q., Huang Z., Ren M., Chang Q., Zhang Z., Parke S. Contraceptive efficacy and safety of estradiol valerate/dienogest in a healthy female population: a multicenter, open-label, uncontrolled Phase III study. Int. J. Womens Health. 2018; 10: 257-66. https://dx.doi.org/10.2147/IJWH.S157056.
  15. Petraglia F., Parke S., Serrani M., Mellinger U., Römer T. Estradiol valerate plus dienogest versus ethinylestradiol plus levonorgestrel for the treatment of primary dysmenorrhea. Int. J. Gynaecol. Obstet. 2014; 125(3): 270-4. https://dx.doi.org/10.1016/j.ijgo.2013.11.017.
  16. Macìas G., Merki-Feld G.S., Parke S., Mellinger U., Serrani M. Effects of a combined oral contraceptive containing oestradiol valerate/dienogest on hormone withdrawal-associated symptoms: results from the multicentre, randomised, double-blind, active-controlled HARMONY II study. J. Obstet. Gynaecol. 2013; 33(6): 591-6. https://dx.doi.org/10.3109/01443615.2013. 800851.
  17. Dinger J., Möhner S., Heinemann K. Combined oral contraceptives containing dienogest and estradiol valerate may carry a lower risk of venous and arterial thromboembolism compared to conventional preparations: Results from the extended INAS-SCORE study. Front. Womens Health. 2020; 5: 1-8. https://dx.doi.org/10.15761/FWH.1000178.
  18. Ahrendt H.J., Makalová D., Parke S., Mellinger U., Mansour D. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel. Contraception. 2009; 80(5): 436-44. https://dx.doi.org/10.1016/j.contraception.2009.03.018.
  19. Fraser I.S., Parke S., Mellinger U., Machlitt A., Serrani M., Jensen J. Effective treatment of heavy and/or prolonged menstrual bleeding without organic cause: pooled analysis of two multinational, randomised, double-blind, placebo-controlled trials of oestradiol valerate and dienogest. Eur. J. Contracept. Reprod. Health Care. 2011; 16(4): 258-69. https://dx.doi.org/10.3109/ 13625187.2011.591456.
  20. Haverinen A.H., Luiro K.M., Szanto T., Kangasniemi M.H., Hiltunen L., Sainio S. et al. Combined oral contraceptives containing estradiol valerate vs ethinylestradiol on coagulation: A randomized clinical trial. Acta Obstet. Gynecol. Scand. 2022; 101(10): 1102-11. https://dx.doi.org/10.1111/aogs.14428.
  21. Meston C.M., Freihart B.K., Handy A.B., Kilimnik C.D., Rosen R.C. Scoring and interpretation of the FSFI: What can be learned from 20 years of use? J. Sex. Med. 2020; 17(1): 17-25. https://dx.doi.org/10.1016/j.jsxm.2019.10.007.
  22. Briggs P., Serrani M., Vogtländer K., Parke S. Continuation rates, bleeding profile acceptability, and satisfaction of women using an oral contraceptive pill containing estradiol valerate and dienogest versus a progestogen-only pill after switching from an ethinylestradiol-containing pill in a real-life setting: results of the CONTENT study. Int. J. Womens Health. 2016; 8: 477-87. https://dx.doi.org/10.2147/IJWH.S107586.
  23. Barnett C., Dinger J., Minh T.D., Heinemann K. Unintended pregnancy rates differ according to combined oral contraceptive – results from the INAS-SCORE study. Eur. J. Contracept. Reprod. Health Care. 2019; 24(4): 247-50. https://dx.doi.org/10.1080/13625187.2019.1629412.
  24. Прилепская В.Н., Довлетханова Э.Р. Гормональная контрацепция с применением комбинированного перорального контрацептива, содержащего эстрадиола валерат/диеногест. Медицинский оппонент. 2022; 2: 46-52. [Prilepskaya V.N., Dovletkhanova E.R. Hormonal сontraception using a combined oral contraceptive containing estradiol valerate/dienogest. Medical. Opponent. 2022; (2): 46-52. (in Russian)].
  25. Young M.F., Oaks B.M., Tandon S., Martorell R., Dewey K.G., Wendt A.S. Maternal hemoglobin concentrations across pregnancy and maternal and child health: a systematic review and meta-analysis. Ann. N. Y. Acad. Sci. 2019; 1450(1): 47-68. https://dx.doi.org/10.1111/nyas.14093.
  26. Куценко И.И., Кравцова Е.И., Холина Л.А., Томина О.В. Терапия латентного железодефицитного состояния у беременных. Гинекология. 2022; 24(6): 512-7. [Kutsenko I.I., Kravtsova E.I., Kholina L.A., Tomina O.V. Latent iron deficiency therapy in pregnant women. Gynecology. 2022; 24(6): 512-7. (in Russian)]. https://dx.doi.org/10.26442/20795696.2022.6.202023.
  27. Jensen J.T., Bitzer J., Nappi R.E., Ahlers C., Bannemerschult R., Parke S. Pooled analysis of bleeding profile, efficacy and safety of oral oestradiol valerate/dienogest in women aged 25 and under. Eur. J. Contracept. Reprod. Health Care. 2020; 25(2): 98-105. https://dx.doi.org/10.1080/13625187.2020.1731734.
  28. Palacios S., Wildt L., Parke S., Machlitt A., Römer T., Bitzer J. Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate/dienogest): a Phase III trial. Eur. J. Obstet. Gynecol. Reprod. Biol. 2010; 149(1): 57-62. https://dx.doi.org/10.1016/j.ejogrb.2009.11.001.
  29. Davis S.R., Bitzer J., Giraldi A., Palacios S., Parke S., Serrani M. et al. Change to either a nonandrogenic or androgenic progestin-containing oral contraceptive preparation is associated with improved sexual function in women with oral contraceptive-associated sexual dysfunction. J. Sex. Med. 2013; 10(12): 3069-79. https://dx.doi.org/10.1111/jsm.12310.
  30. Caruso S., Agnello C., Romano M., Cianci S., Lo Presti L., Malandrino C., Cianci A. Preliminary study on the effect of four-phasic estradiol valerate and dienogest (E2V/DNG) oral contraceptive on the quality of sexual life. J. Sex. Med. 2011; 8(10): 2841-50. https://dx.doi.org/10.1111/ j.1743-6109.2011.02409.x.
  31. De Seta F., Restaino S., Banco R., Conversano E., De Leo R., Tonon M. et al. Effects of estroprogestins containing natural estrogen on vaginal flora. Gynecol. Endocrinol. 2014; 30(11): 830-5. https://dx.doi.org/ 10.3109/09513590.2014.936847.
  32. Di Carlo C., Gargano V., De Rosa N., Tommaselli G.A., Sparice S., Nappi C. Effects of estradiol valerate and dienogest on quality of life and sexual function according to age. Gynecol. Endocrinol. 2014; 30(12): 925-8. https://dx.doi.org/10.3109/09513590.2014.975688.
  33. Юренева С.В., Ильина Л.М. Комбинированные оральные контрацептивы с натуральным эстрогеном и сексуальная функция: оптимальный метод контрацепции для женщин различного возраста. Гинекология. 2019; 21(1): 33-7. [Yureneva S.V., Ilina L.M. Combined oral contraceptives with natural estrogen and sexual function: the optimal method of contraception for women of different ages. Gynecology. 2019; 21(1): 33-7. (in Russian)]. https://dx.doi.org/ 10.26442/20795696.2019.1.190184.
  34. de Castro Coelho F., Barros C. The potential of hormonal contraception to influence female sexuality. Int. J. Reprod. Med. 2019; 2019: 9701384. https://dx.doi.org/10.1155/2019/9701384.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Figure. Distribution of patients

Download (259KB)
Indexing metadata

Copyright (c) 2024 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies